AMVAC® and NewLeaf Symbiotics® Partner to Bring Biological Solutions to North American Crop Markets

NEWPORT BEACH, Calif.–(BUSINESS WIRE)–American Vanguard® The company (NYSE: AVD), through its wholly owned subsidiary AMVAC Chemical Corporation, is pleased to announce a new partnership with NewLeaf Symbiotics.® from St. combined technical resources of both companies. This partnership will expand and accelerate American Vanguard’s growing GreenSolutions™ biologics portfolio and facilitate NewLeaf Symbiotics’ goal of securing broader market penetration.

AMVAC will leverage its deep market reach, strong sales teams in US agricultural markets, and GreenSolutions™ growing portfolio of biologics. In the United States GreenSolutions AMVAC recently passed the 1.2 million acre mark for application, a milestone for the company in the fast-growing organic segment. AMVAC has previously announced biologics partnerships with 3Bar Biologics, BASF, and Azotic North America.

NewLeaf Symbiotics brings to the partnership its proprietary microbial library, proven research and development capabilities and existing product offering including natural microbes that provide a variety of benefits to crops throughout the growing season. Leading this new class of ag biologics is Terrasym® microbial inoculants, which can make plants more robust, resistant and tolerant to abiotic stress throughout their life cycle.

“AMVAC’s GreenSolutions and precision application technologies are key strategic growth initiatives built on the strong foundation of a highly successful, five-decade crop protection chemistry business,” said Bob Trogele, COO and Executive Vice President, AMVAC. “AMVAC continues to innovate by leveraging its in-house research capabilities as well as establishing partnerships with leading biologics companies. With NewLeaf Symbiotics, we look forward to increasing access to value-added biologics that benefit North American farmers.” .”

Steve Kahn, CEO of NewLeaf Symbiotics said, “AMVAC provides long-term access to partnerships in North American markets that are critical to the growth of the ag biologics sector. NewLeaf Symbiotics, as a major player in biologics, is excited to partner with expand our North American market penetration with AMVAC Longer term, we expect to see further synergies in the technology and product lines of our two companies.

About NewLeaf Symbiotics

NewLeaf Symbiotics is an agricultural biotechnology company that discovers, develops, manufactures and commercializes products containing beneficial plant microbes. Its team has grown to 35+ members, including 12 PhD scholars. NewLeaf has filed more than 150 patents and patent applications and introduced its first biostimulant products in the United States for corn and soybeans, Terrasym 450 and Terrasym 401.

About American Vanguard

American Vanguard Corporation is a specialty and diversified agricultural products company that develops and markets products for crop protection, turf and ornamental plant management, and public safety applications. American Vanguard is included in the Russell 2000® & Russell 3000® Indices and the Standard & Poors® Small Cap 600 Index. AMVAC® is a subsidiary of Vanguard® Corporation of America.

The Company may, from time to time, discuss forward-looking information. Such forward-looking statements are estimates of the Company’s management and are subject to various risks and uncertainties that could cause results to differ materially from management’s current expectations. Such factors are detailed in the Company’s SEC reports and filings. All forward-looking statements represent the Company’s judgment as of the date of this release.

For more information on products and services visit

©2022 AMVAC Chemical Company is a wholly owned subsidiary of American Vanguard Corporation. All rights reserved. American Vanguard, AMVAC, GreenSolutions, and related logos are trademarks owned by AMVAC Chemical Corporation.

All other trademarks are the property of their respective owners.


Also Read :  What To Expect As Interest Rates Rise

Leave a Reply

Your email address will not be published.